Table 2.
aPercentages are based on response and PFS status of only those patients who were taking corticosteroids at baseline. Sustained reduction was defined as ≥50% corticosteroid dose reduction, relative to baseline, for ≥50% of time on study drug.
Abbreviations: BEV, bevacizumab; CPT-11, irinotecan; PFS, progression-free survival.